The Management of Gonorrhea in the Era of Emerging Antimicrobial Resistance

Gonorrhea rates continue to rise in the United States and Neisseria gonorrhoeae ’s propensity to develop resistance to all therapies used for treatment has complicated the management of gonorrhea. Ceftriaxone is the only remaining highly effective recommended regimen for gonococcal treatment and few new anti-gonococcal antimicrobials are being developed. The 2021 CDC STI Trea tment Guidelines increased the dose of ceftriaxone to 500 mg (1 g if ≥ 150 kg) for uncomplicated infections. It is recommended that all clinicians should be aware of antimicrobial resistant gonorrhea and be able to appropriately manage any suspected gonorrhea treatment failure case.
Source: Medical Clinics of North America - Category: Primary Care Authors: Source Type: research